The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903] - Wikidata - awgldk - TriplyDB

The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

http://www.wikidata.org/entity/Q24797790

about

The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature A comprehensive review on metabolic syndrome CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials The metabolic syndrome A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.Important considerations for treatment with dietary supplement versus prescription niacin products.Safety and tolerability of extended-release niacin with laropiprant.Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.Investigation of niacin on parameters of metabolism in a physiologic dose: randomized, double-blind clinical trial with three different dosages.

P2860

Q21245908-46FBAA3F-8898-4BBA-A7F4-B2059585E400 Q21284500-D7EE031A-4FF5-4B48-A79C-849A63980DEE Q24614627-E6DB4C5B-75B3-4C27-9E15-759A8FD7EC7A Q33569142-9786D737-A144-4D6E-A462-04D8E84FF6F3 Q33765072-FFEF7EEF-08D5-49F0-A482-740CA62E02E7 Q35142685-5D0B965A-FE7B-45B0-A904-B5817B5F45AA Q35931525-8BBA2742-932C-4E03-87F0-A2D381844881 Q36691540-6A437373-B333-4A63-8326-B2FA6512B9C9 Q37336045-68FB194A-F2E4-4FF2-9BF5-D4638DFA927D Q37862929-FFF84EC8-AFD6-4FE0-9AF5-CEB5784BE41A Q37963506-89088692-17A9-4666-9C6B-81D5B31A72B4 Q38765419-2148CC5E-AEBA-4066-937D-849AB74AAD9E Q40365888-C2344D30-5F23-41C1-869C-B35679330A29 Q43144693-863B705C-0825-49B4-B251-356DBDD6610A Q43159242-DB27AE0C-B311-4B4B-A2C0-D4B4C5013C8F Q43182514-90FF18B0-838D-432C-B82C-08CEF1E61A2B Q44652704-36E7D38A-8F1A-4525-A594-EE249119F078 Q45971694-51503852-6A41-4EB5-B422-96B96B9B36FF

P2860

The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

http://www.wikidata.org/entity/Q24797790

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@ast

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@en

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@nl

type

label

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@ast

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@en

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@nl

prefLabel

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@ast

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@en

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@nl

P1433

Q24797790-8A01EA19-E1F9-489A-9E10-3D4F17CBBF22

P1476

Q24797790-48C84969-6A6E-48B0-A890-06C846DF0977

P2093

Q24797790-08516615-64F4-4973-B14C-20ED2677577F

Q24797790-2278D93F-919D-46FF-B41E-A5189ED1CC8B

Q24797790-4D0428AD-9AA3-421A-A975-50A4D5FE9827

Q24797790-ADC0E3BA-59D9-4686-B506-13CD071052A6

Q24797790-D0849C35-D7B5-4CAE-88E4-68D13CEBDF91

Q24797790-FA7E219B-2855-4776-9C00-BEC09F95D626

P2860

Q24797790-22239895-A059-4841-B04F-732B044DDDF1

Q24797790-25215162-1A45-45BA-9F1E-05DA82274D67

Q24797790-2675C07E-9A45-46AD-832C-42A91A891794

Q24797790-26AB9DDB-9849-4871-8969-7EE990B29070

Q24797790-2E275F42-9EB5-44CF-936F-F459437B2B7E

Q24797790-38F3BDCA-4A51-4916-BC63-4C0908CEF45C

Q24797790-4819B674-F460-4E0C-86F5-CFC6057DEE2D

Q24797790-7C4DBB76-8A60-4E0F-ABF9-BA74328C3503

Q24797790-84F27D6A-707C-4DB8-BD97-D5169B8E74D0

Q24797790-8E8530FB-34E7-40A2-AF11-F4C5A87F2EFD

P2888

Q24797790-884E13CF-C960-46C1-AF58-2FC71586C79C

P304

Q24797790-B1048529-AF16-4B91-819E-38DFADEB6034

P31

Q24797790-132661E4-62EE-4D44-ACE5-D11D0EC677CB

P3181

Q24797790-B2F1FE7A-5176-4BD7-98F3-6F9BF233B00E

P356

Q24797790-928E484D-5D1F-4F07-B2F2-D0E6AAC3A2AE

P407

Q24797790-ED5C57F7-E9A1-4606-BF3C-1E3A48E11FAF

P433

Q24797790-7E9C0125-0DB1-487A-A2DE-E600A5425A04

P478

Q24797790-25C5EE00-DC56-4804-8DE0-B342685F30E2

P50

Q24797790-F384A8CE-43B1-4799-9F7F-B743FC164F18

P577

Q24797790-ACCFB413-D9B4-4AA7-AEC7-E0692996077D

P5875

Q24797790-57E147C7-C5E5-462B-AD18-F7323876EDB2

P6179

Q24797790-6416F522-E490-41E1-B355-A1B29F6BAFEB

P698

Q24797790-55C4DD3B-22E8-4A10-9F90-4674D86B6344

P921

Q24797790-9A1EBF40-03BE-49DA-9D9F-78861AA4E43E

P932

Q24797790-2F352A8A-157B-4437-816E-D79B285B71D2

P3181

P356

P1433

BMC Clinical Pharmacology

P1476

The safety of over-the-counter ...... trolled trial [ISRCTN18054903]

@en

P2093

Beth Rachlis

http://www.w3.org/2001/XMLSchema#string

David Juurlink

http://www.w3.org/2001/XMLSchema#string

Edward Mills

http://www.w3.org/2001/XMLSchema#string

Gannady Raskin

http://www.w3.org/2001/XMLSchema#string

Joel Gagnier

http://www.w3.org/2001/XMLSchema#string

Jonathan Prousky

http://www.w3.org/2001/XMLSchema#string

P2860

Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Adverse drug reactions: keeping up to date.

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.

Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.

Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies.

Attitudinal survey of voluntary reporting of adverse drug reactions

P2888

P304

4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3070008

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1472-6904-3-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Victor M. Montori

P577

2003-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9011107

http://www.w3.org/2001/XMLSchema#string

P6179

1021618500

http://www.w3.org/2001/XMLSchema#string

P698

14614780

http://www.w3.org/2001/XMLSchema#string

P921

P932

280687

http://www.w3.org/2001/XMLSchema#string